Related Experiment Videos
Detection of truncated dystrophin in fetal DMD myotubes
I B Ginjaar1, E Bakker, J T den Dunnen
1Dept. of Human Genetics, Sylvius Laboratory, Leiden, The Netherlands.
Abstract:
An immunohistochemical study was carried out on a twelve-week old fetus, aborted for high risk of Duchenne muscular dystrophy. Southern and FIGE analysis showed an intragenic duplication in the DMD gene, which had previously resulted in a severe Duchenne phenotype in three relatives. Polyclonal antibodies directed against the NH2-terminal half of dystrophin showed a positive reaction an a similar distribution of dystrophin in the skeletal myotubes of a twelve-week old normal fetus and the affected fetus. In contrast, a polyclonal antibody directed against the COOH-terminus of dystrophin, i.e., distal to the mutation in this family, did only react with the myotubes of the normal fetus and not with those of the affected fetus. This indicates the presence of a truncated dystrophin in the affected fetus. Apparently at this stage, before binding of dystrophin to the sarcolemma, no distinction is made yet between normal and abnormal dystrophins. This implies that the potential to bind to the sarcolemma could be a major point of discrimination between normal and defective dystrophins. The truncated dystrophin will probably be degraded in a later stage during fetal development. So it appears that the use of dystrophin immunostaining to confirm high Duchenne risk abortions requires great caution. To prevent false-positive results, the combined use of NH2- and COOH-terminal antibodies is mandatory.
Insights
Immunohistochemistry for Duchenne muscular dystrophy (DMD) requires caution. Using both NH2- and COOH-terminal antibodies is essential to detect truncated dystrophin and prevent false-positive results in high-risk abortions.
Area of Science:
- Genetics
- Neurology
- Biochemistry
Background:
- Duchenne muscular dystrophy (DMD) is a severe genetic disorder.
- Genetic testing can identify high-risk pregnancies for DMD.
- Immunohistochemistry is used to assess dystrophin expression.
Purpose of the Study:
- To evaluate the utility of dystrophin immunostaining in confirming high-risk Duchenne muscular dystrophy abortions.
- To investigate the expression of dystrophin in an affected fetus with an intragenic DMD gene duplication.
Main Methods:
- Immunohistochemical analysis of fetal muscle tissue using antibodies against dystrophin's NH2- and COOH-termini.
- Southern and FIGE analysis to confirm intragenic duplication in the DMD gene.
Main Results:
- An intragenic duplication in the DMD gene was identified in the affected fetus.
- Dystrophin was detected in both normal and affected fetal myotubes using an NH2-terminal antibody.
- Dystrophin was absent in the affected fetus's myotubes using a COOH-terminal antibody, indicating truncated dystrophin.
Conclusions:
- The study indicates the presence of truncated dystrophin in the affected fetus.
- Dystrophin's ability to bind to the sarcolemma may be crucial for distinguishing normal from defective forms.
- Combined use of NH2- and COOH-terminal antibodies is mandatory for accurate diagnosis in high-risk Duchenne muscular dystrophy abortions to avoid false positives.